Oncothyreon is focused on robust clinical development of its pipeline programs. Our trials are designed to evaluate the safety and efficacy of our product candidates, and to provide data that helps to advance these candidates toward approval and the market. In selecting cancer indications for clinical trials, we pair the target and mechanism of action of each of our candidates with the molecular profiles of specific cancers. We also seek to address cancer indications that have limited treatment options and substantial unmet medical need. This approach allows for data-driven decision making and creates opportunities for generating value in the clinic and the marketplace.
Learn more about the indications we are investigating with the products in our pipeline.